SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

LYBALVI

ALKS·Alkermes plc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially available (FDA approved May 28, 2021). A pediatric label expansion, if supported by the ENLIGHTEN-Youth trial, would be a supplemental approval, typically 6-12 months after data submission.
Why 4/10
LYBALVI is already FDA-approved and commercially marketed with no pending regulatory decision. The next hard catalyst is topline data from the ENLIGHTEN-Youth Phase 3 pediatric trial (primary completion Sep 2026, results not yet reported as of Nov 4, 2026), but this is not a dated binary event. LYBALVI is one of four marketed products at Alkermes (alongside VIVITROL, ARISTADA, and LUMRYZ), so it is not a single-asset binary. ImpactScore of 4 reflects an approved drug with commercial momentum but no imminent regulatory binary.
Actionable Insight NEUTRAL

Watch for topline results from the ENLIGHTEN-Youth Phase 3 pediatric trial (primary completion Sep 2026, results unreported as of Nov 4). Positive data could support a label expansion into adolescents, opening a new patient segment. Separately, LYBALVI's expanded payer access (~80% of covered lives) should drive prescription volume growth into 2027, though gross-to-net adjustments are expected to rise to ~45%.

Price Chart

Loading chart...

Executive Summary

LYBALVI (olanzapine and samidorphan) is an FDA-approved oral atypical antipsychotic from Alkermes plc (Nasdaq: ALKS) for adults with schizophrenia and bipolar I disorder. Its key differentiator is samidorphan, which mitigates the weight gain that olanzapine alone typically causes. Approved in May 2021, LYBALVI generated $95.9M in Q3 2026 net sales (18% prescription growth YoY) and $346.7M in full-year 2025. The drug faces a crowded competitive field of newer antipsychotics (Caplyta, Vraylar, Rexulti) and generic olanzapine. A Phase 3 pediatric trial (ENLIGHTEN-Youth) with primary completion in September 2026 could support label expansion into adolescents, but results have not yet been reported. LYBALVI is one of four marketed products at Alkermes, which also has a pipeline of orexin 2 receptor agonists. Analyst consensus is bullish (20 Buy/Strong Buy, mean PT $56.21), but the stock faces near-term headwinds from rising gross-to-net adjustments and elevated short volume.

How It Works

LYBALVI combines two drugs in one pill: olanzapine, a standard atypical antipsychotic that controls schizophrenia and bipolar symptoms by blocking dopamine and serotonin receptors, and samidorphan, which blocks opioid receptors to counteract the weight gain and metabolic side effects that olanzapine typically causes. Clinical trials show patients on LYBALVI gain about 37-50% less weight than those on olanzapine alone.

Trial Status

LYBALVI is FDA-approved and commercially marketed for adults with schizophrenia and bipolar I disorder. A Phase 3 pediatric trial (ENLIGHTEN-Youth, NCT05303064) comparing LYBALVI to olanzapine in adolescents (schizophrenia ages 13-17, bipolar I ages 10-17) had a primary completion date of September 2026; topline results have not been announced as of November 4, 2026. Long-term open-label extension data through four years has been previously reported showing sustained safety and efficacy.

The Two-Sided Case

▲ Bull Case5
LYBALVI is a differentiated product: the samidorphan component mitigates olanzapine-induced weight gain by ~37-50% versus olanzapine alone, addressing a key metabolic side effect that limits olanzapine use.
Q3 2026 LYBALVI net sales reached $95.9M with 18% year-over-year prescription growth, and proprietary product net sales overall grew 31% YoY to $417.3M.
Payer access expanded to ~80% of covered lives, which management expects to drive prescription volume acceleration into 2027.
The ENLIGHTEN-Youth Phase 3 pediatric trial (NCT05303064) could support label expansion into adolescents (schizophrenia ages 13-17, bipolar I ages 10-17), opening a new patient population.
Analyst consensus is bullish: 20 Buy/Strong Buy ratings vs. 6 Hold and 1 Sell, with a mean price target of $56.21 (23% upside from $45.69). Major institutional holders like BlackRock ($1.53B), Baker Bros. ($525M), and Vanguard ($497M) added to positions in Q2 2026.
▼ Bear Case5
Intense competition in the atypical antipsychotic market from Caplyta (lumateperone), Vraylar (cariprazine), Rexulti (brexpiprazole), Latuda (lurasidone) and generic olanzapine limits LYBALVI's market share potential.
Gross-to-net adjustments are expected to rise from ~42% in Q3 2026 to ~45% in 2027 as expanded payer access comes with higher rebates, pressuring net sales growth.
Elevated short-sale volume (63.2% of off-exchange volume vs. a 49.9% baseline, z-score 3.15) and insider selling under 10b5-1 plans signal bearish sentiment around the stock.
Q3 2026 EPS of $0.09 missed the $0.25 consensus estimate, and GAAP net income fell sharply to $16.3M from $82.8M a year earlier due to higher R&D and SG&A costs.
ENLIGHTEN-Youth pediatric trial primary completion (Sep 2026) has passed with no topline results announced yet, creating uncertainty around the label-expansion timeline.

Upcoming Catalysts

  • ENLIGHTEN-Youth Phase 3 pediatric trial topline results (primary completion Sep 2026, results pending)
  • Potential sNDA submission for pediatric label expansion if ENLIGHTEN-Youth is positive
  • LYBALVI prescription volume acceleration as expanded payer access (~80% of covered lives) matures through 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Alkermes plc. 8-K ALKS ·Originating report

Sources · 13

Hover a chip for the title
1 biospace.com2 drugs.com3 fool.com4 tickeron.com5 seekingalpha.com6 clinicaltrials.gov7 psychiatrist.com8 investor.alkermes.com9 marketbeat.com10 stockanalysis.com11 ainvest.com12 stocktitan.net13 sec.gov